UPDATE: Exercise of Options to Provide Novogen with $690K -6K

Novogen Limited

today announced that it had signed an Underwriting Agreement with Lodge Partners to underwrite the outstanding options exercisable at $0.125 per option, which expire on 18 November 2015. The exercise of options will provide the Company with an additional $690K (before costs), which will reinforce the Company's financial position and will be directly allocated to help fund its Phase 1 clinical trial for Cantrixil, which is expected to start in 2016